May 12, 2022 4:05pm EDT Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
May 01, 2022 11:25pm EDT Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
May 01, 2022 2:00pm EDT Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Apr 26, 2022 4:05pm EDT RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
Mar 23, 2022 7:00am EDT Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
Feb 22, 2022 7:00am EST Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
